PTC Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Good afternoon, everyone. I'm Andrew Galler, one of the biotech analysts here at Morgan Stanley, and I'm pleased to be joined today from PTC Therapeutics, Matt Klein, COO; and Kylie O'Keefe, who is the Head of Communications and Global Corporate Strategy.
So I think -- and then before we get started, I want to read out some disclosures. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Questions & Answers
So to start off, I think that PTC is really in a transformational period right now, based on some of the recent milestones you hit and then also some upcoming data catalysts. So maybe if you want to take a few minutes to start to just
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |